Status:
TERMINATED
Safety and Efficacy of Double Staining With Brilliant Blue G for Macular Surgery
Lead Sponsor:
Asociación para Evitar la Ceguera en México
Conditions:
Macular Hole
Epiretinal Membrane
Eligibility:
All Genders
18-90 years
Phase:
PHASE3
Brief Summary
Study designed to evaluate the safety and efficacy of double staining with brilliant blue G 0.025% as an adjuvant to macular surgery. Patients undergoing surgery for macular hole or epiretinal membran...
Eligibility Criteria
Inclusion
- Patient age 18 years of older
- Signing of informed consent
- Macular pathology requiring vitrectomy (epiretinal membrane, macular hole, vitreomacular traction syndrome)
Exclusion
- Diagnosis of glaucoma
- Known allergy to brilliant blue G
Key Trial Info
Start Date :
January 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2014
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT01820520
Start Date
January 1 2013
End Date
February 1 2014
Last Update
May 30 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asociación para Evitar la Ceguera en México
Mexico City, Mexico City, Mexico, 04030